Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
You may also be interested in...
ImCheck Therapeutics Pursues Immuno-Oncology Antibodies
Emerging Company Profile: The new anticancer antibody developer ImCheck Therapeutics has set up in Marseille, France, a location that is becoming increasingly attractive to biotech start-ups that could rival more established areas in coming years.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways